• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by BioLife Solutions, Inc. (Amendment)

    10/29/21 8:00:18 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BLFS alert in real time by email
    SC 13D/A 1 wv20211029_sc13da.htm SCHEDULE 13D/A wv20211029_sc13da.htm

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)

     

    BioLife Solutions, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    09062W204

    (CUSIP Number)

     

    Michael Rice, Chief Executive Officer
    3303 Monte Villa Parkway, Suite 310
    Bothell, Washington 98021

    (425) 402-1400

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    August 26, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    SCHEDULE 13D

    CUSIP NO. 09062W204

     

    1.

    NAME OF REPORTING PERSON

     

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Walter Villiger

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

       

    (b) ☐

     

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS*

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ☐

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

     

     

    NUMBER OF

    7.

    SOLE VOTING POWER  1,979,226

     

    SHARES

       
     

    BENEFICIALLY

    8.

    SHARED VOTING POWER  0

     

    OWNED BY

       
     

    EACH

    9.

    SOLE DISPOSITIVE POWER  1,979,226

     

    REPORTING

       
     

    PERSON WITH

    10.

    SHARED DISPOSITIVE POWER  0

     

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,979,226 shares held indirectly through Reporting Person’s wholly-owned entity named WAVI Holding AG (“WAVI”)

     

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

       

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) *

     

    4.86%

       

    14.

    TYPE OF REPORTING PERSON*

     

    IN  

     

     

     

     

    SCHEDULE 13D

    CUSIP NO. 09062W204

     

    1.

    NAME OF REPORTING PERSON

     

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    WAVI Holding AG

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

       

    (b) ☐

     

    3.

    SEC USE ONLY

       

    4.

    SOURCE OF FUNDS*

     

    OO

       

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  ☐

       

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

     

     

    NUMBER OF

    7.

    SOLE VOTING POWER  1,979,226

     

    SHARES

       
     

    BENEFICIALLY

    8.

    SHARED VOTING POWER  0

     

    OWNED BY

       
     

    EACH

    9.

    SOLE DISPOSITIVE POWER  1,979,226

     

    REPORTING

       
     

    PERSON WITH

    10.

    SHARED DISPOSITIVE POWER  0

     

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,979,226 shares of common stock held directly by WAVI

     

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

       

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) *

     

    4.86%

       

    14.

    TYPE OF REPORTING PERSON*

     

    CO

     

     

     

     

    Item 5.  Interest in Securities of the Issuer.

    -------------------------------------------

    Item 5 is hereby amended and supplemented as follows:

     

    On August 9, 2021, WAVI Holding AG (“WAVI”) sold 28,068 shares of common stock of the Issuer, on August 25, 2021, WAVI sold another 300,000 shares of common stock of the Issuer, on August 26, 2021, WAVI sold another 208,816 shares of common stock of the Issuer, on August 27, 2021, WAVI sold another 100,000 shares of common stock of the Issuer, on August 30, 2021, WAVI sold another 100,000 shares of common stock of the Issuer, on August 31, 2021, WAVI sold another 48,860 shares of common stock of the Issuer, on September 1, 2021, WAVI sold another 50,000 shares of common stock of the Issuer, on September 2, 2021, WAVI sold another 3,010 shares of common stock of the Issuer, on October 25, 2021, WAVI sold another 105,000 shares of common stock of the Issuer, and on October 26, 2021, WAVI sold another 80,000 shares of common stock of the Issuer.

     

    As of the date hereof, Mr. Villiger beneficially owns 1,979,226 shares of common stock held indirectly through WAVI. Such shares represent a total of 4.86% of the Issuer’s outstanding shares of common stock as of August 9, 2021 as reported by the Company in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 16, 2021. 

     

    Mr. Villiger has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above. Except WAVI with respect to the securities held by WAVI, there are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.

     

    As of the date hereof, WAVI directly owns 1,979,226 shares common stock. Such shares represent a total of 4.86% of the Issuer’s outstanding shares of common stock as of August 9, 2021 as reported by the Company in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 16, 2021.

     

    Mr. Villiger has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above. Except Mr. Villiger, there are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of such securities.  

    On October 26, 2021, both Mr. Villiger and WAVI ceased to own in excess of 5% of the outstanding shares of common stock of the Issuer.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  October 29, 2021

    /s/ Walter Villiger

     
     

    Walter Villiger

     
         

    Dated:  October 29, 2021

    WAVI HOLDING AG

     
         
     

    /s/ Walter Villiger

     
     

    Walter Villiger, Chairman

     

     

     

     

     

     

     

     
    Get the next $BLFS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLFS

    DatePrice TargetRatingAnalyst
    7/22/2025$30.00Overweight
    Stephens
    9/30/2024$29.00Buy
    H.C. Wainwright
    4/4/2024$22.00Buy
    Jefferies
    7/11/2023$29.00Buy
    Craig Hallum
    4/25/2022$28.00Perform → Outperform
    Oppenheimer
    10/19/2021$61.00Buy
    B. Riley Securities
    10/15/2021$64.00Outperform
    Cowen
    8/13/2021$50.00 → $60.00Overweight
    Keybanc
    More analyst ratings

    $BLFS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by BioLife Solutions Inc.

    SCHEDULE 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    8/21/25 9:35:50 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

    8/21/25 4:20:40 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by BioLife Solutions Inc.

    10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

    8/7/25 4:22:52 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioLife Solutions Reports Second Quarter 2025 Financial Results

    Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene th

    8/7/25 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Makes Strategic Investment in Pluristyx

    BOTHELL, Wash., July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle based developer of innovative induced pluripotent stem cell (iSPC) based products for cell therapy developers. BioLife also entered into a separate agreement which provides a board observer seat, and certain rights related to any potential future acquisition of Pluristyx.

    7/28/25 8:05:00 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025

    BOTHELL, Wash., July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Rel

    7/24/25 4:05:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Casdin Partners Master Fund, L.P. sold $12,200,000 worth of shares (500,000 units at $24.40) (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    8/21/25 9:10:03 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Casdin Partners Master Fund, L.P. sold $11,300,000 worth of shares (500,000 units at $22.60) (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    8/13/25 6:43:14 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Technology Officer Werner Sean sold $23,660 worth of shares (1,115 units at $21.22), decreasing direct ownership by 4% to 26,495 units (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    7/22/25 5:33:30 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on BioLife Solutions with a new price target

    Stephens resumed coverage of BioLife Solutions with a rating of Overweight and set a new price target of $30.00

    7/22/25 7:51:31 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    H.C. Wainwright initiated coverage on BioLife Solutions with a new price target

    H.C. Wainwright initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

    9/30/24 7:39:39 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on BioLife Solutions with a new price target

    Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00

    4/4/24 7:31:02 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Casdin Partners Master Fund, L.P. bought $10,374,976 worth of shares (927,165 units at $11.19) (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    10/23/23 5:42:32 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

    SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    2/13/24 5:00:45 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

    SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    1/24/24 4:16:40 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by BioLife Solutions Inc. (Amendment)

    SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    10/24/23 4:29:23 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Financials

    Live finance-specific insights

    View All

    BioLife Solutions Reports Second Quarter 2025 Financial Results

    Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene th

    8/7/25 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025

    BOTHELL, Wash., July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Rel

    7/24/25 4:05:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Reports First Quarter 2025 Financial Results

    Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

    5/8/25 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Leadership Updates

    Live Leadership Updates

    View All

    BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

    BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an

    3/18/25 8:30:00 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

    BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

    12/16/24 8:11:00 AM ET
    $BLFS
    $RGEN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

    Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.

    8/25/22 8:03:00 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care